Navigation Links
Molecular Biomarkers for Cancer Detection and Management

London (PRWEB) November 07, 2013

New to Insight Pharma Reports is Molecular Biomarkers for Cancer Detection and Management: Technologies, Markets, and Trends. This report focuses on recent progress and new directions in this highly dynamic diagnostic field. Covering extensive background and history, commercialization, and marketing trends of cancer biomarker technologies, this report provides heavy detail of historical and evolutionary aspects of cancer biomarkers, delineating some of the difficulties researchers face in validating and commercializing their candidate assays.

Significant highlights of the report include:

•Basic research conducted in both academic and commercial settings divided into three segments: disease detection, prognosis, and companion diagnostics.
-42 detailed descriptions of copmanies (including GenomeDx Biosciences, Genomic Health, Life Technologies, Foundation Medicine, Roche Molecular Systems, and many more!).
•Commercial activity in the three foregoing sectors, and the perspective of market dynamics.
•Focuses on trends and conclusions.
•Data depicted across 15 tables and figures.

Following company descriptions and commercial applications are transcribed interviews of five individuals who are highly knowledgeable in the field, including:

•Genome Diagnostics
•Billings Clinic
•Scientia Advisors
•Cynvenio Biosystems
•Johns Hopkins University School of Medicine

Also provided in the report are survey results of 107 individuals who actively work in the cancer biomarker space. Results are depicted across 9 tables.

Table of Contents

Executive Summary
•Background and history
•Basic research
•Commercial applications
•Market dynamics
•Survey results
•Trends and conclusions

CHAPTER 1: Introduction
•Scope and contents

CHAPTER 2: Background and History
•First-generation cancer biomarkers
•Categorization of cancer biomarkers
•Disease detection biomarkers
•Prognostic biomarkers
•Companion diagnostic biomarkers
•Omic era cancer biomarkers
•Failed efforts and stumbling blocks

CHAPTER 3: Basic Research
•Screening, detection, risk, and monitoring
•Prognosis and prediction
•Companion Diagnostics
•Circulating tumor cells
•MicroRNA (miRNA)

CHAPTER 4: Commercial Applications
•Screening, detection, risk assessment, and monitoring biomarkers
•Allegro Diagnostics
•Atossa Genetics
•Biophysical Corporation
•Exact Sciences
•Exosome Diagnostics
•MDx Health
•Myriad Genetics
•Predictive Biosciences
•Prognosis and prediction biomarkers
•Abbott Molecular
•Atossa Genetics
•GenomeDx Biosciences
•Genomic Health
•Life Technologies
•Predictive Biosciences
•Skyline Diagnostics
•Companion diagnostic biomarkers
•20/20 GeneSystems
•Abbott Molecular
•Dako (Agilent)
•Epic Sciences
•Foundation Medicine
•Genomic Health
•Molecular Response Corp.
•Personal Genome Diagnostics
•Interview with founder, Luis Diaz, MD
•Roche Molecular Systems

CHAPTER 5: Market Dynamics
•Competitive Environment
•Sales Estimates and Projections
•Mergers and acquisitions
•Cancer detection, risk, and prognostic assay deals
•Liquid Biopsy AB and Roche
•Oxford Gene Technology
•Abbott and Stanford University
•Ipsogen and Personal Genome Diagnostics (PDGx)
•Companion diagnostic assay deals
•Abbott and Merck
•Affymetrix and Massachusetts General Hospital (MGH)
•Agilent/Dako and Genentech
•Eli Lilly
•Foundation Medicine
•GE Healthcare and Insight Genetics
•Genomic Health and OncoMed Pharmaceuticals
•HTG Molecular Diagnostics and Merck
•Life Technologies and Others
•Qiagen and Boehringer Ingelheim
•Quintiles and Oxford Cancer Biomarkers
•Roche/Ventana and other companies
•Verastem and Labcorp
•Survey Results

CHAPTER 6: Observations and Conclusions
•Companion diagnostics
•Circulating tumor cells and nucleic acids
•EMT biomarkers
•Tumor Heterogeneity
•Costs and reimbursement

CHAPTER 7: Interview Transcripts
•Luis Diaz, MD, Associate Professor of Oncology, Johns Hopkins School of Medicine; Chief Medical Officer and Founder Personal Genome Diagnostics
•Jorge Nieva, MD, Oncologist and Hematologist,Billings Clinic,Billings Montana
•Harry Glorikian, Managing Partner and Founder, Scientia Advisors
•Paul Dempsey, Ph.D., Chief Science Officer, CynvenioBiosystems
•Scott Kern, M.D., Professor of Oncology and Pathology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
•About Cambridge Healthtech Institute


•Exhibit 4.1 Screening, detection, risk, and monitoring biomarkers
•Exhibit 4.2 Prognosis and prediction biomarkers
•Exhibit 4.3 Companion diagnostic biomarkers
•Exhibit 5.1 Estimated cancer biomarker manufacturer revenues (2012) and projections (2017), by segment (US$ in billions)
•Exhibit 5.2 Selected recent cancer detection, risk, and prognostic assay deals
•Exhibit 5.3 Selected recent companion diagnostic assay deals
•Exhibit 5.4 Survey: Area of respondents’ work
•Exhibit 5.5 Survey: Nature of respondents’ organization
•Exhibit 5.6 Survey: Respondents’ position within their organization
•Exhibit 5.7 Survey: Respondent’s biomarker focus (Multiple answers permitted; n=107)
•Exhibit 5.8 Survey: Respondents’ organization employs which of the following technologies for cancer biomarker detection of measurement (Multiple answers permitted; n=100)
•Exhibit 5.9 Survey: Statements regarding circulating tumor cells and nucleic acids (Multiple answers permitted; n=100)
•Exhibit 5.10 Survey: Participation in companion diagnostics (Multiple answers permitted; n=100)
•Exhibit 5.11 Survey: On a scale of 1 to 5, please rate the following entities as likely sources for new cancer biomarkers during the next five years (1=Highly unlikely; 5=Highly likely)
•Exhibit 5.12 Survey: On a scale of 1 to 5, please rate the following technologies as likely means for detecting or measuring cancer biomarkers during the next five years (1=Highly unlikely; 5=Highly likely)


•Figure 4.1 Cynvenio's LiquidBiopsy Platform

Read the full report:

Molecular Biomarkers for Cancer Detection and Management

For more information:
Sarah Smith
Research Advisor at
Tel: +44 208 816 85 48

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Coordinating the circadian clock: Molecular pair controls time-keeping and fat metabolism
2. Molecular probes identify changes in fibronectin that may lead to disease
3. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
4. Molecular subtypes and genetic alterations may determine response to lung cancer therapy
5. Scientists discover distinct molecular subtype of prostate cancer
6. New molecular structure offers first picture of a protein family vital to human health
7. Grb2 holds powerful molecular signaling pathway in check
8. Better treatment for brain cancer revealed by new molecular insights
9. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
10. Researchers unveil molecular details of how bacteria propagate antibiotic resistance
11. Molecular switch identified that controls key cellular process
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced ... User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics ... software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ...
(Date:11/27/2015)... Minn. (PRWEB) , ... November 27, 2015 , ... ... start failing. Secura Consultants has prided itself for not only fulfilling the needs ... income protection solutions at an affordable price and providing top-tier customer service. However, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... CBD College ... of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. ... accredited colleges, as only one of twelve colleges and universities in the state of ...
(Date:11/27/2015)... ... ... Dr. Thomas Dunlap and Dr. Patrick Coleman , cardiologist ... Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted the ... ways and require time-critical intervention to avoid large area heart damage and progressive infections ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., ... the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 ... brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015  The American Academy of Pediatrics (AAP), ... the March of Dimes cheered today,s signature into ... Act of 2015 (S.799), which takes much-needed ... exposed to drugs, such as opioids, and to ... three organizations have worked together leading advocacy efforts ...
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
(Date:11/25/2015)... Kitov Pharma ceuticals ... biopharmaceutical company focused on the development of therapeutic candidates ... announced the closing of its previously announced underwritten public ... each representing 20 ordinary shares of the Company, and ... and warrants were issued in a fixed combination of ...
Breaking Medicine Technology: